Research area · Emerging treatment technologies
Araştırma alanı dosyası (tek çalışma değil): kişiye özel neoantijen mRNA aşıları
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
What is being studied? A personalized vaccine based on the tumor’s genetics tries to teach the immune system to recognize the cancer. This is a research area, not one drug name.
Why promising? Hypothesis of teaching the immune system tumor-specific targets to cut recurrence risk; randomized phase IIb signal in melanoma.
What is not proven? “49% of patients were cured” is a misreading. The 49% figure is relative risk reduction for recurrence/death in the KEYNOTE-942 ~3-year update (HR 0.51). The primary Lancet analysis is separate. No phase III generalization yet.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
Site priority: very high. Keep Lancet 2024 primary (HR 0.561) separate from ASCO 2024 ~3y update (49% RRR, HR 0.510; nominal p). Child cards: KEYNOTE-942, V940-001, Autogene. ELI-002 is not mRNA — not linked under this area.
Cancer / population: Melanoma, Pancreas, Multiple / solid tumors — Araştırma alanı — alt kartlarda tümör tipine göre
Intervention: Kişiye özel neoantijen mRNA aşı ± PD-1
Primary endpoint: Alan düzeyinde tek primer sonlanım yok
Limitations: Teknoloji alanı ≠ tek çalışma. Assay/üretim lojistiği ve tümör tipine özgü sonuçlar ayrı okunmalı.
Each card is a separate clinical or discovery record — not one NCT.
Interim analysis
Melanoma
Phase IIb: primary Lancet HR 0.561; ~3y update ~49% relative RFS risk reduction — not a 49% cure rate.
Registry checked: 2026-10-29
Melanoma
Phase III confirmation; enrollment closed. Separate confirmatory trial of the KEYNOTE-942 phase IIb signal.
Registry checked: 2026-10-29
Interim analysis
Pancreas
Pancreatic mRNA vaccine phase I; early immune/follow-up signals — not standard care.
Registry checked: 2026-10-29